Last updated 5 days ago
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
130 patients around the world
Available in United States, Brazil
Johnson & Johnson Enterprise Innovation Inc.
1Research sites
130Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening.Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization.Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification.Have at least 1 target lesion (primary lung lesion or involved lymph node[s]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening.Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1.
- Medical history of: Primary immunodeficiency, Organ transplant that requires therapeutic immunosuppression.Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV.Another concurrent or prior primary malignancy within the last 36 months at informed consent.Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab.History of coagulation disorders, including: Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization.
Sites
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
Recruiting
StudyCONVERGE
SponsorJohnson & Johnson Enterprise Innovation Inc.
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06667908
